Related Experiment Video
Updated: Jan 23, 2026

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
Published on: January 7, 2022
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai1, Zhan Zhou2, Zhuchu Chen3
1NHC Key Laboratory of Cancer Proteomics & Laboratory of Structural Biology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China. syandai@hotmail.com.
Abstract:
Fibroblast growth factor receptors (FGFRs) are a family of receptor tyrosine kinases expressed on the cell membrane that play crucial roles in both developmental and adult cells. Dysregulation of FGFRs has been implicated in a wide variety of cancers, such as urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma. Due to their functional importance, FGFRs have been considered as promising drug targets for the therapy of various cancers. Multiple small molecule inhibitors targeting this family of kinases have been developed, and some of them are in clinical trials. Furthermore, the pan-FGFR inhibitor erdafitinib (JNJ-42756493) has recently been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic or unresectable urothelial carcinoma (mUC). This review summarizes the structure of FGFR, especially its kinase domain, and the development of small molecule FGFR inhibitors.
Insights
Fibroblast growth factor receptors (FGFRs) are crucial in cell development and implicated in various cancers. This review covers FGFR structure and the development of small molecule inhibitors, including the approved drug erdafitinib.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Fibroblast growth factor receptors (FGFRs) are receptor tyrosine kinases vital for cellular functions.
- FGFR dysregulation is linked to numerous cancers, including urothelial, liver, ovarian, and lung cancers.
- FGFRs represent significant therapeutic targets in oncology.
Purpose of the Study:
- To review the structural characteristics of FGFRs, focusing on the kinase domain.
- To summarize the development of small molecule inhibitors targeting FGFRs.
- To highlight the therapeutic potential of FGFR inhibition in cancer treatment.
Main Methods:
- Literature review of FGFR structure and function.
- Analysis of small molecule inhibitor development pipelines.
- Examination of clinical trial data and drug approvals.
Main Results:
- FGFRs possess a kinase domain critical for their signaling.
- Numerous small molecule FGFR inhibitors have been developed, with several in clinical trials.
- Erdafitinib, a pan-FGFR inhibitor, is FDA-approved for metastatic urothelial carcinoma.
Conclusions:
- FGFRs are validated drug targets in oncology.
- Small molecule inhibitors offer a promising therapeutic strategy for FGFR-driven cancers.
- Targeted therapies like erdafitinib represent advancements in cancer treatment.
More Related Videos
09:16Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
Published on: September 11, 2015
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
Related Concept Videos
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Influencing Microbial Growth: pH
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity
Olfactory Receptors: Location and Structure
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...